Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 17 points (-0.1%) at 17,039 as of Tuesday, July 15, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 915 issues advancing vs. 2,069 declining with 174 unchanged.

The Health Services industry currently sits down 0.8% versus the S&P 500, which is down 0.3%. A company within the industry that increased today was Edwards Lifesciences ( EW), up 0.6%. On the negative front, top decliners within the industry include Accelerate Diagnostics ( AXDX), down 9.3%, Boston Scientific ( BSX), down 2.6%, Stryker Corporation ( SYK), down 1.2% and Abbott Laboratories ( ABT), down 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Smith & Nephew ( SNN) is one of the companies pushing the Health Services industry higher today. As of noon trading, Smith & Nephew is up $0.72 (0.8%) to $88.00 on average volume. Thus far, 159,924 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 251,300 shares. The stock has ranged in price between $87.80-$88.48 after having opened the day at $88.10 as compared to the previous trading day's close of $87.28.

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $15.7 billion and is part of the health care sector. Shares are up 21.7% year-to-date as of the close of trading on Monday. Currently there are 5 analysts who rate Smith & Nephew a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Smith & Nephew as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Smith & Nephew Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Quest Diagnostics ( DGX) is up $0.60 (1.0%) to $60.83 on average volume. Thus far, 916,096 shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $60.38-$61.28 after having opened the day at $60.38 as compared to the previous trading day's close of $60.23.

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $8.6 billion and is part of the health care sector. Shares are up 12.5% year-to-date as of the close of trading on Monday. Currently there are 2 analysts who rate Quest Diagnostics a buy, 3 analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Quest Diagnostics Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Aetna ( AET) is up $0.52 (0.6%) to $82.68 on light volume. Thus far, 796,556 shares of Aetna exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $82.00-$82.95 after having opened the day at $82.16 as compared to the previous trading day's close of $82.16.

Aetna Inc. operates as a diversified health care benefits company in the United States. The company operates in three segments: Health Care, Group Insurance, and Large Case Pensions. Aetna has a market cap of $29.2 billion and is part of the health care sector. Shares are up 19.8% year-to-date as of the close of trading on Monday. Currently there are 12 analysts who rate Aetna a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Aetna as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Aetna Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null